EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Importance of oxyphil cells for 99mTc-sestamibi uptake in primary hyperparathyroidism: a retrospective observational study

Jan Axl Dropmann, Axel Kleespies, Heinrich Fuerst, Marcus Kremer, Moritz Drefs, Michael Neuberger

Nuklearmedizin - NuclearMedicine · 01.06.2025 · 64 (03) · 215-224

DOI: 10.1055/a-2535-1067 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2025. Verfasst von Jan Axl Dropmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: LMU University Hospital, Department of General, Visceral and Transplantation Surgery, Ludwig Maximilian University of Munich, München, Germany. Hauptthemen laut MEDLINE: Technetium Tc 99m Sestamibi, Hyperparathyroidism, Primary, Oxyphil Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with primary hyperparathyroidism (pHPT), the importance of oxyphil cells for 99mTc-sestamibi uptake is uncertain. This retrospective observational study of pHPT patients evaluated independent associations between oxyphil cell content (OCC) and preoperative scintigraphic (SC) findings, using logistic regression analyses. We studied 76 patients with pHPT before and after operation. Preoperative SC was able to definitively identify abnormal parathyroid tissue in 47 patients (61.8%). The median relative OCC (postoperative histopathological examination) was 10% (IQR 0.25% – 40%) and the median absolute OCC was 0.09 cm3 (IQR 0.00 – 0.59 cm3). After adjustment for confounders, an iPTH concentration >200 pg/ml and increasing OCC was the only significant independent predictor of a definitively positive SC result (per category of relative OCC: adjusted odds ratio (aOR) 2.40, 95% confidence interval (CI) 1.02 – 5.65, p=0.045). In patients with pHPT, a higher OCC was associated with a significantly higher probability of a clearly positive SC finding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technetium Tc 99m SestamibiHyperparathyroidism, PrimaryOxyphil CellsHumansFemaleMaleRetrospective StudiesMiddle AgedRadiopharmaceuticalsAgedRadionuclide ImagingReproducibility of ResultsSensitivity and Specificity

Substanzen

Technetium Tc 99m SestamibiRadiopharmaceuticals

Autor:innen und Institutionen

  • LMU University Hospital, Department of General, Visceral and Transplantation Surgery, Ludwig Maximilian University of Munich, München, Germany.
  • Department of General, Visceral, Thoracic and Oncological Surgery, HELIOS Amper-Klinikum Dachau, Dachau, Germany.
  • Division of Thyroid Surgery, Isar Klinikum, München, Germany.
  • Institute of Pathology, München Klinik Neuperlach, Munchen, Germany.

Zitieren

APA

Dropmann, J. A., Kleespies, A., Fuerst, H., Kremer, M., Drefs, M., & Neuberger, M. (2025). Importance of oxyphil cells for 99mTc-sestamibi uptake in primary hyperparathyroidism: a retrospective observational study. Nuklearmedizin - NuclearMedicine, 64(03), 215-224. https://doi.org/10.1055/a-2535-1067

Vancouver

Dropmann JA, Kleespies A, Fuerst H, Kremer M, Drefs M, Neuberger M. Importance of oxyphil cells for 99mTc-sestamibi uptake in primary hyperparathyroidism: a retrospective observational study. Nuklearmedizin - NuclearMedicine. 2025;64(03):215-224. doi:10.1055/a-2535-1067

BibTeX
@article{Dropmann2025,
  author = {Dropmann, Jan Axl and Kleespies, Axel and Fuerst, Heinrich and Kremer, Marcus and Drefs, Moritz and Neuberger, Michael},
  title = {Importance of oxyphil cells for 99mTc-sestamibi uptake in primary hyperparathyroidism: a retrospective observational study},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2025},
  volume = {64},
  number = {03},
  pages = {215--224},
  doi = {10.1055/a-2535-1067}
}
Kostenlos starten →